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Abstract The severity and complexity of depression can vary widely among individuals, thus 
making single drug therapy ineffective in some cases. Taking this fact into account and 
using a mouse model, we set on investigating the possibility of obtaining a synergism of 
action between a classical tricyclic antidepressant that inhibits noradrenalin and serotonin 
reuptake (doxepin), and a modern antidepressant that inhibits type-B monoamine oxidase 
(selegiline). We measured the antidepressant effect using the forced swimming test and 
the tail suspension test. We determined motor activity using the Activity Cage test. Our 
results have shown that the antidepressant effect intensifies significantly in the animals 
treated with both antidepressants simultaneously compared to those treated only with 
doxepin. Furthermore, we observed that selegiline decreases the sedative effect of doxepin 
in the Activity Cage test. 
Keywords  doxepin, selegiline, antidepressant, pharmacological research 
Highlights ✓ Selegiline plus doxepin double drug therapy increases significantly the antidepressant 
effect 
✓ Selegiline plus doxepin double drug therapy prevents the sedative side effect of doxepin 
administered as a single drug therapy 
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Introduction 
Depression is becoming a global problem due to the 
stress caused by the adaptation difficulties that our high-
speed way of life currently demands (1). Mood disorders 
have been studied for decades and many theories have been 
proposed to explain the cause of depression. The original 
monoamine theory of depression suggested a direct 
involvement of the adrenergic system in the onset of this 
disorder (2). Later studies demonstrated a more complex 
relationship between the various endogenous 
neurotransmissions, suggesting an indirect role of the 
adrenergic system in depression as it modulates the 
function of other transmissions (3).     
The first significant breakthrough in the treatment of 
depressive disorders occurred 60 years ago with the 
approval of imipramine, thus opening a path for an entire 
class of drugs—tricyclic antidepressants—which act as 
nonselective noradrenergic and serotoninergic reuptake 
inhibitors (4). At the same time, compounds with other 
mechanisms such as monoamine oxidase inhibitors, 
enhanced the synaptic concentration of catecholamines and 
achieved similar positive effects on the symptoms of 
depression (5).  
Selegiline was created by Joseph Knoll almost 60 years 
ago and since then, it has been widely used for the 
treatment of Parkinson`s disease in low doses, Alzheimer`s 
disease, and major depression in higher doses (6). 
Selegiline acts in 3 ways: it reduces dopamine 
biotransformation through the inhibition of type B 
monoamine oxidase; it inhibits the dopamine reuptake; and 
it stimulates dopamine synthesis by blocking the 
presynaptic dopamine receptors (7).  
Although many therapeutic options are currently 
available, there are still cases of antidepressant-resistant 
depressions that require either new molecules (8-11) or 
new approaches in managing these disorders (12). Given 
that a new drug requires significant time and financial 
resources, combining existent therapies may prove to be a 
viable solution for treating complex atypical depressions. 
Materials and Methods 
A population of 70 white male NMRI mice having 
reached maturity and weighing 34 ± 6g was supplied by the 
rodent farm of “Carol Davila” University of Medicine and 
Pharmacy. Animals were kept in cages for 24 hours 
separately from other animals in order to reduce stress and 
ensure a gradual transition to the new environment. Later, 
they were housed in ventilated Plexiglas cages containing 
groups of 10 individuals with free access to food and water. 
Temperature and humidity were constant (21-23°C; 45-
55%) and monitored with an Eco Solar TFA30.1037 
thermo-hygrometer.  
All experiments were conducted in accordance with 
the EU Directive 63/2010, Romanian Law 43/2014 and 
Good Animal Practice Regulations. The protocol was 
approved by the Bioethics Committee of “Carol Davila” 
University.  
The 70 mice were initially subjected to the Activity 
cage test in order to configure the research groups. 
Horizontal motor activity (Ugo Basile 47420 Multiple 
Activity Cage unit) measured in 5-minute intervals was the 
parameter used to identify individuals fit for this 
experiment. After excluding individuals with extreme 
responses, the 60 remaining mice were divided into 5 
groups, each containing 12 animals, in such a manner that 
the average responses and the standard deviations were as 
similar as possible. Animals were then allowed two days 
for acclimation in their new groups. On the day of the 
experiment, each group was brought to the lab, two hours 
before being treated, in order to allow adaptation to the new 
environment where they were kept without food. 
The 5 groups were treated as follows: 
• Group I (control) – distilled water 0.1 ml/ 10g orally 
• Group II – Doxepin 10 mg/ kg bw suspension 0.1% 
orally 
• Group III – Doxepin 15 mg/ kg bw suspension 0.15% 
orally 
• Group IV – Doxepin 10 mg/ kg bw suspension 0.1% + 
Selegiline 2.5 mg/ kg bw suspension 0.25% orally 
• Group V – Doxepin 15 mg/ kg bw suspension 0.15% + 
Selegiline 5 mg/ kg bw suspension 0.5% orally 
The substances used in this experiment were: 
• Doxepin hydrochloride D4526 – Sigma Aldrich, USA 
• Selegiline hydrochloride S0360000 – Sigma Aldrich, 
USA 
The tests were executed as follows:  
• After one administration – the forced swimming test 
• After 1 week of daily administrations (including the 
testing day) – the tail suspension test and the Activity 
cage test 
• After 2 weeks of daily administrations (including the 
testing day) – the tail suspension test and the Activity 
cage test 
Testing began one hour after the drugs were 
administered.  
All testing followed a specific protocol: in the testing 
area, animals were kept in artificial light, without food. 
Each individual was administered the treatment with an 8-
minute delay from the next one (5 minutes for the Activity 
cage test; 6 minutes for the forced swimming and tail 
suspension tests and 2 additional minutes to clean or 
prepare the devices before testing another animal) so that 
all of them could be tested after the same time interval from 
the moment of receiving the treatment. 
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Assessment of motor activity was conducted to assess 
the effect on the central nervous system by recording the 
horizontal and vertical movements of each mouse in the 
Ugo Basile – Activity Cage. The animals were placed 
individually in a corner of the cage and their movements 
were recorded for 5 minutes by IR photoelectric cell 
sensors (9, 13).  
Assessment of immobility time of mice as a marker of 
antidepressant activity was conducted in two tests: 
• The forced swimming test (FST) consists of placing 
each mouse in a glass cylinder (25 cm height, 30 cm 
diameter) containing a 20 cm high column of water at a 
temperature of 21 ± 1°C and recording the number of 
seconds it rests afloat motionless during a 4-minute 
interval after a prior 2-minute interval for 
accommodation (14, 15, 16). 
• The tail suspension test (TST) consists of suspending a 
mouse by its own tail in such a manner that it cannot 
touch neighboring surfaces nor escape. The animal is 
maintained in this position for 6 minutes and in the last 
4 minutes, the number of seconds spent motionless is 
recorded (17, 18). 
Statistics  
For the statistical evaluation, the GraphPad Prism 5.0 
software was used. This software analyzes populations 
with Gaussian distribution using the Student t-test (for 2 
groups) and the ANOVA test (for multiple groups). In case 
of statistical significance in the ANOVA (p < 0.05), a 
further post-test was conducted (Dunnett). The normality 
of the distribution was determined using the D`Agostino – 
Pearson test. 
Results and Discussions 
1. Antidepressant activity  
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Figure 1. Immobilization time + SD in FST 
after a single dose. 
The forced swimming test performed after the acute 
administration revealed unsurprising results in the test 
groups compared to the control group. Even though 
statistical significance was not achieved, a higher decrease 
in the immobilization time was noticed in the groups 
treated with the combination selegiline + doxepin, 
compared to control, versus the groups treated only with 
doxepin. 
TST after 7 days
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Figure 2. Immobilization time + SD in TST after 7 
days of treatment. 
Table 1. Immobilization time results in forced swimming test 
Parameter 
Group I 
(Control) 
Group II   
(Doxepin 
10mg/kg  
bw) 
Group III 
(Doxepin 
15mg/kg  
bw) 
Group IV 
(Doxepin 
10mg/kg bw + 
Selegiline 
2.5mg/kg  
bw) 
Group V 
(Doxepin 
15mg/kg bw 
+ Selegiline 
5mg/kg  
bw) 
Normal 
Distribution  
(D&P) 
YES YES YES YES YES 
M 148.5 145.3 144.1 141.3 140.2 
SD 40.14 43.41 37.05 42.2 45.63 
Variation (%) of 
immobilization 
time vs Control 
- -2.15% -2.96% -4.85% -5.59% 
ANOVA p > 0.05 
Dunnett - ns ns ns ns 
M = average; SD = standard deviation; D&P = D`Agostino – 
Pearson test; ns = statistically not significant. 
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Figure 3. The evaluation of the antidepressant effect in 
TST after 7 days of treatment 
In the immobilization test, after 7 days of treatment, the 
antidepressant effect of the doxepin + selegiline 
combination in high doses compared to control is more 
potent than the single drug doxepin therapy, as is shown by 
statistical significance. 
Figure 4. Immobilization time + SD in TST after 
14 days of treatment 
  
Table 3. Immobilization time results in tail suspension test after 14 days of treatment 
Parameter 
Group I 
(Control) 
Group II 
(Doxepin 
10mg/kg bw) 
Group III 
(Doxepin 
15mg/kg bw) 
Group IV 
(Doxepin 
10mg/kg bw + 
Selegiline 
2.5mg/kg bw) 
Group V (Doxepin 
15mg/kg bw + Selegiline 
5mg/kg bw) 
Normal 
Distribution 
(D&P) 
YES YES YES YES YES 
M 140.3 124.6 95.42 81.33 72.42 
Table 2. Immobilization time results in tail suspension test after 7 days of treatment 
Parameter 
Group I 
(Control) 
Group II 
(Doxepin 
10mg/kg bw) 
Group III 
(Doxepin 
15mg/kg bw) 
Group IV (Doxepin 
10mg/kg bw + 
Selegiline 2.5mg/kg 
bw) 
Group V 
(Doxepin 
15mg/kg bw + 
Selegiline 
5mg/kg bw) 
Normal 
Distribution (D&P) 
YES YES YES YES YES 
M 151.8 120.7 111.4 109.3 72.08 
SD 27.46 21.16 28.18 25.84 29.76 
Variation (%) of 
immobilization 
time vs Control 
- -20.49% -26.61% -28% -52.52% 
ANOVA p < 0.001 
Dunnett - * ** ** *** 
M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; * = statistically significant; ** = 
statistically very significant; *** = statistically extremely significant. 
The antidepressant effect of associating doxepin and selegiline 
 265 
SD 43.04 43.21 39.07 20.54 22.59 
Variation (%) of 
immobilization 
time vs Control 
- -11.19% -31.99% -42.03% -48.38% 
ANOVA p < 0.001 
Dunnett - ns * *** *** 
M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; ns = statistically not significant; * = 
statistically significant; *** = statistically extremely significant. 
 
2. Motor behavior  
Table 4. Horizontal motor activity in 5 minutes after a 7-day treatment 
Parameter 
Group I 
(Control) 
Group II 
(Doxepin 
10mg/kg bw) 
Group III 
(Doxepin 
15mg/kg bw) 
Group IV 
(Doxepin 
10mg/kg bw + 
Selegiline 
2.5mg/kg bw) 
Group V (Doxepin 
15mg/kg bw + Selegiline 
5mg/kg bw) 
Normal 
Distribution 
(D&P) 
YES YES YES YES YES 
M 405.4 354.7 318.8 465.1 495.5 
SD 62.97 54.25 44.38 55.78 60.83 
Variation (%) of 
HMA vs Control 
- -12.5% -21.36% +16.1% +17.56% 
ANOVA p < 0.001 
Dunnett - ns ** * *** 
M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; HMA = horizontal motor activity; ns = 
statistically not significant; * = statistically significant; ** = statistically very significant; *** = statistically 
extremely significant. 
. 
 
 
Figure 5. The evaluation of the antidepressant 
effect in TST after 14 days of treatment 
After a two-week treatment period, the effectiveness 
of combining selegiline with doxepin intensifies in both 
groups, while the group treated with a low doxepin dose 
tends to become less effective compared to the control 
group. The statistical significance of the immobilization 
time decrease was noticeably stronger in the groups 
treated with the two combined antidepressants. 
Figure 6. Horizontal motor activity + SD after 7 
days of treatment 
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Table 5. Vertical motor activity in 5 minutes after a 7-day treatment 
Parameter 
Group I 
(Control) 
Group II 
(Doxepin 
10mg/kg bw) 
Group III 
(Doxepin 
15mg/kg bw) 
Group IV 
(Doxepin 
10mg/kg bw + 
Selegiline 
2.5mg/kg bw) 
Group V 
(Doxepin 
15mg/kg bw + 
Selegiline 5mg/kg 
bw) 
Normal 
Distribution 
(D&P) 
YES YES YES YES YES 
M 29.58 22.70 20.33 29.92 33.33 
SD 9.07 6.717 6.401 10.77 13.3 
Variation (%) of 
VMA vs Control 
- -23.25% -31.27% +1.14% +12.67% 
ANOVA p < 0.05 
Dunnett - ns ns ns ns 
M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; VMA = vertical motor activity; ns = 
statistically not significant. 
  
  
  
Figure 7. Evolution of the horizontal motor 
activity after one week compared to the control 
group. 
Figure 8. Evolution of the horizontal motor activity after 
one week in the groups treated with the combination of 
selegiline + doxepin versus groups treated only with 
doxepin (*** - p<0.001 in t-Student test) 
 
 
Figure 9. Vertical motor activity + SD after 7 days 
of treatment 
Figure 10. Evolution of the vertical motor activity after 
one week compared to the control group 
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.
 After one week of treatment, both the horizontal and 
the vertical motor activity decreases in the groups treated 
only with doxepin in a dose-dependent manner, which was 
expected due to its known sedative profile. However, this 
phenomenon is completely annulled, even reversed, in a 
statistically significant way (in case of HMA) for the 
groups treated with the doxepin + selegiline combination 
compared to the control group. 
 
Table 6. Horizontal motor activity in 5 minutes after a 14-day treatment 
Parameter 
Group I 
(Control) 
Group II 
(Doxepin 
10mg/kg bw) 
Group III 
(Doxepin 
15mg/kg bw) 
Group IV 
(Doxepin 
10mg/kg bw + 
Selegiline 
2.5mg/kg bw) 
Group V 
(Doxepin 
15mg/kg bw + 
Selegiline 
5mg/kg bw) 
Normal 
Distribution 
(D&P) 
YES YES YES YES YES 
M 452.6 413.2 373.4 465.3 531.6 
SD 70.97 80.98 73.31 70.31 77.02 
Variation (%) 
of HMA vs 
Control 
- -8.71% -17.5% +2.81% +17.45% 
ANOVA p < 0.001 
Dunnett - ns * ns * 
M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; HMA = horizontal 
motor activity; ns = statistically not significant; * = statistically significant. 
  
Figure 11. Horizontal motor activity + SD after 14 
days of treatment 
Figure 12. Evolution of the horizontal motor activity 
after two weeks compared to the control group 
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Figure 13. Evolution of the horizontal motor 
activity after two weeks in the groups treated 
with the combination of selegiline + doxepin 
versus groups treated only with doxepin (*** - 
p<0.001 in t-Student test) 
Figure 14. Vertical motor activity + SD after 14 days of 
treatment 
Table 7. Vertical motor activity in 5 minutes after a 14-day treatment 
Parameter 
Group I 
(Control) 
Group II 
(Doxepin 
10mg/kg bw) 
Group III 
(Doxepin 
15mg/kg bw) 
Group IV 
(Doxepin 
10mg/kg bw + 
Selegiline 
2.5mg/kg bw) 
Group V 
(Doxepin 
15mg/kg bw + 
Selegiline 5mg/kg 
bw) 
Normal 
Distribution 
(D&P) 
YES YES YES YES YES 
M 51.73 47.33 40 63.50 73.82 
SD 16.61 8.773 11.33 16.83 14.81 
Variation (%) of 
VMA vs Control 
- -8.51% -22.68% +22.75% +42.7% 
ANOVA p < 0.001 
Dunnett - ns ns ns ** 
M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; VMA = vertical motor activity; ns = 
statistically not significant; ** = statistically very significant. 
 
Figure 15. Evolution of the vertical motor activity 
after two weeks compared to the control group 
After two weeks of treatment, the increase of HMA in 
the groups treated with the selegiline + doxepin 
combination compared to the control group is maintained, 
although the statistical significance is lower than the one 
registered after the first week of treatment. VMA 
intensifies after 14 days of treatment in the same groups 
compared to control, versus the 7-day determination. The 
sedative effect of doxepin administered by itself decreases 
in the 2nd week compared to the first, which is consistent 
with existing data in the scientific literature regarding the 
use of doxepin in long time treatments. 
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Conclusions 
Selegiline in association with doxepin induced a slight 
reduction in the immobilization time, compared to doxepin 
administered alone, in FST after the acute treatment.  
After a 7-day treatment, the most intense anti-
depressant effect compared to the control group was 
registered in the groups treated with doxepin 10 mg/kg bw 
+ selegiline 2.5 mg/kg bw (-28%; p<0.01) and doxepin 15 
mg/kg bw + selegiline 5 mg/kg bw (-52.52%; p<0.001). 
Comparing the single drug doxepin therapy with the 
combined doxepin + selegiline therapy, the antidepressant 
effect almost doubled when using the combination in 
higher dosages. 
After a 14-day treatment, the most intense 
antidepressant effect compared to the control group 
continued to register in the groups treated with doxepin 10 
mg/kg bw + selegiline 2.5 mg/kg bw (-42.03%; p<0.001) 
and doxepin 15 mg/kg bw + selegiline 5 mg/kg bw (-
48.38%; p<0.001). Comparing the single drug doxepin 
therapy with the combined doxepin + selegiline therapy, 
the combination of the two antidepressants continued to be 
more effective, although the difference in intensity 
between the effect of the single drug therapy and that of the 
double drug therapy decreased, especially in the case of 
higher dosages.  
Assessing the motor activity registered after 7 and 14 
days of treatment, selegiline not only canceled the sedative 
effect of doxepin, but to some extent, reversed it. This 
phenomenon is more obvious and significant in HMA than 
in VMA.  
Based on our analysis, we conclude that a selegiline + 
doxepin combination therapy not only significantly 
increases the antidepressant effect, but also prevents the 
sedative side effect of doxepin administered as a single 
drug therapy. 
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